Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Epic American Credit and Bond Bubble Laboratory -- Ignore unavailable to you. Want to Upgrade?

To: patron_anejo_por_favor who wrote (25218)	1/24/2005 7:24:23 PM
From: Henry Niman	Respond to of 110194

Tamiflu is in the hopes and dreams category. Its expensive, has to be taken continuously, in short supply, and doesn't work well on N1, including H5N1. Roche is building a new plant in the US and other countries are talking about making generics, but the only reason its being considered is there isn't anything else (virus is resistant to Rimantadine and Amantadine). Tami flu was used to try to rescue the tigers in the Thai Zoo, but they all died (147 out of 441 but the survivors were probably never exposed). Best hope is a vaccine, but that was delayed because it was declared a select agent because the gene was modified to make the virus less lethal. I'm not sure how long it took to get ruling reversed, but trials have been delayed and won;t start for 406 weeks for Aventis (Chiron built a new facility, so they are behind Aventis)